Multistage judgment type high-precision detection method, system and kit

Through the binding molecular coupling and signal inhibitor in the kit system, the problems of low detection sensitivity and high cost in high interference samples are solved, and high throughput, low interference and low cost detection effects are achieved.

CN119044497AActive Publication Date: 2024-11-29ZYBIO INC

Patent Information

Application Number
CN202411202320.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-29
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

Existing immunoassay technologies are low in detection sensitivity and cost in high interference samples, and solid-phase cleaning steps increase instrument complexity and detection time.

Method used

Using a kit system, including reagent A and reagent B, the binding molecules in which are coupled by a flexible connecting unit can specifically bind and generate optical signals without the need for solid phase carriers, reducing non-essential cleaning steps, and suppressing binding signals. to reduce background interference.

Benefits of technology

It significantly reduces detection cost, improves detection throughput and sensitivity, reduces the frequency of solid-phase materials, and is suitable for accurate detection of high-interference samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005018128750000057
    Figure BDA0005018128750000057
  • Figure BDA0005018128750000161
    Figure BDA0005018128750000161
  • Figure BDA0005018128750000171
    Figure BDA0005018128750000171
Patent Text Reader

Abstract

The invention discloses a multi-stage judgment type target object detection method and system and a detection kit, the detection kit comprises a reagent with a structure connected with a solid phase carrier, and the detection method and the detection system with multi-stage judgment steps and corresponding modules are matched. The reagent is matched with the solid-phase carrier containing the connecting structure for use in the testing process according to sample testing requirements, so that the reagent is flexible to use and can be matched with different detection requirements; therefore, the detection method and system integrate the advantages of a solid phase cleaning detection technology and a homogeneous phase detection technology, not only avoids unnecessary cleaning when the whole sample is detected in a solid phase mode, but also avoids the problem of low accuracy caused by existence of a special sample when the whole sample is detected in a homogeneous phase mode.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of in vitro diagnosis, and in particular to an immunoassay method and system and a kit. Background Art

[0002] In the past 40 years, immunoassay technology has undergone a transformation from radioimmunoassay technology, enzyme-linked immunosorbent assay technology to magnetic microparticle chemiluminescence technology. With the continuous improvement of detection sensitivity, many biomarkers with great clinical value have been applied to clinical diagnosis. Luminescence detection methods containing solid-phase washing steps, such as magnetic microparticle chemiluminescence technology, have gradually replaced enzyme-linked immunosorbent technology and occupied nearly 90% of the market share. Although magnetic microparticle chemiluminescence technology is used on a large scale in clinical practice due to its sensitivity and specificity, it also exposes some limitations. First, the action of magnetic washing increases the difficulty of the instrument's liquid path module and the cost of the instrument; secondly, because of the action of magnetic washing, the detection throughput of the detection instrument is limited. The inspection department with a large sample detection volume needs to extend the working time or add multiple devices to meet the detection needs. In order to avoid the complexity brought about by solid-phase washing such as magnetic beads, some homogeneous detection technologies, such as spatial proximity chemiluminescence, have gradually achieved technological breakthroughs.

[0003] In the spatial proximity chemiluminescence technology, one antibody involved in the immune reaction is labeled with horseradish peroxidase (HRP), and the other antibody involved in the immune reaction is labeled with a luminescent compound, such as acridine ester (AE). In the presence of the target antigen, a sandwich immune complex can be formed. The target antigen can make the HRP and AE labeled on the two antibodies closely connected together, and generate a light signal under the action of the substrate. The intensity of the light signal is proportional to the concentration of the target antigen. The relevant technology has been disclosed in WO2010099486A1. Its technical advantages are: ① Based on the immune reaction of antigen and antibody, an immune complex is formed, and the amount of the complex is monotonically related to the amount of the object to be tested; the immune reaction of antigen and antibody ensures the specificity of the detection. ② The immune reaction occurs in a homogeneous system, and the homogeneous reaction ensures a high precision of the detection; ③ Based on the proximity of the positions of HRP and AE to generate a signal, the instrument does not need a liquid system to achieve magnetic cleaning, the instrument has low cost, small size, and can achieve high throughput.

[0004] However, spatial proximity luminescence technology still has some limitations. For example, there is no magnetic cleaning process in the reaction process, which cannot remove interferences in the sample. The detection results for high-interference samples are poor. For example, hemolytic and lipemia samples that often appear in some elderly people will interfere with the immune response, thereby affecting the accuracy of the test results. Compared with magnetic particle chemiluminescence, the detection sensitivity is relatively low.

[0005] In summary, existing detection technologies all have certain limitations. Clinical scenarios urgently need a fully automatic, high-throughput detection technology with lower cost, lower interference and higher sensitivity to meet clinical needs. Summary of the invention

[0006] The purpose of the present invention is to provide a kit and a testing method and system for detecting target objects. The kit and the detection method can reduce the number of unnecessary sample cleanings, reduce the frequency of use of solid phase material detection methods, significantly reduce costs, and improve detection throughput. It can also avoid the problems of low sensitivity and accuracy caused by special samples.

[0007] Therefore, one aspect of the present invention is to provide a target detection kit, the kit comprising reagent A and reagent B, the reagent A containing a first binding molecule, the first binding molecule coupled to compound 1;

[0008] The reagent B contains a second binding molecule, and the second binding molecule is coupled to compound 2;

[0009] The first binding molecule and / or the second binding molecule further comprises at least one connecting structure I;

[0010] Among them, the compound 1 has the function of catalyzing the compound 2 to generate a signal; the first binding molecule and the second binding molecule can specifically bind to the target in the sample to form a specific binding complex; and the connection structure I does not form a specific binding state.

[0011] The working concentration of the first binding molecule complex coupled with compound 1 in reagent A is 0.1-3.0 μg / mL; the working concentration of the second binding molecule complex coupled with the compound in reagent B is 0.1-3.0 μg / mL.

[0012] "Target" refers to a certain biochemical substance or substances whose specific content or concentration you want to know through detection means.

[0013] "Catalysis" means changing the activation free energy required for the reaction through a catalyst, thereby changing the chemical reaction rate of the reactants. Compound 1 does not act directly on compound 2, but rather causes compound 2 to react chemically with other substances through "catalysis".

[0014] Furthermore, the first binding molecule and the second binding molecule are not coupled to a solid phase carrier.

[0015] Further, the kit also includes reagent C, which contains compound 3. Wherein, compound 2 and compound 3 react to generate a detectable signal, such as a light signal; when the first binding molecule in the kit is coupled with compound 1, the first binding molecule coupled with compound 1 and the second binding molecule coupled with compound 2 are combined with the target to be detected, the distance between compound 1 and compound 2 is sufficient for compound 1 to catalyze compound 2 to generate a detectable signal, while phosphatase and compound 2 cannot generate a detectable signal at the same distance, so further, compound 1 is not a phosphatase, such as alkaline phosphatase.

[0016] Furthermore, compound 1 and compound 2 are coupled to the first binding molecule and the second binding molecule respectively through a flexible connection unit.

[0017] The "flexible linking unit" is a non-rigid substance. When the first binding molecule and the second binding molecule coupled with compound 1 and compound 2 form a complex with the target to be detected, compound 1 and compound 2 can move around the periphery of the complex based on the softness of the "flexible linking unit" so that the substance that can generate the luminescent signal is close enough in space to generate a detectable signal. The "flexible linking unit" is selected from polyoxyethylene ether substances, polyoxypropylene ether substances, alkyl, polyethyleneimine substances, polypeptides and blocks of the above substance composition units. In order to ensure the luminous efficiency, the flexible linking unit should not be too long. Therefore, it is preferred that the total effective length of the flexible linking unit linking compound 1 and compound 2 is less than or equal to 200nm, preferably less than 180nm, and more preferably less than 150nm; at the same time, the total length should be greater than the diameter of the binding molecule; or the total degree of polymerization of the flexible linking unit is less than 500.

[0018] "Polyoxyethylene ethers" are also called polyethylene oxide (PEO) or polyoxyethylene (POE) substances, and refer to polymers with a PEG main chain, preferably a PEG main chain and a class of compounds with active groups at the chain ends that can be connected to biological molecules, such as NHS-(PEG)n, Pierce TM PEG-SPDP series.

[0019] "Alkyl" includes straight-chain alkyl, branched alkyl or alkylene groups having an active group at the end of the chain, and the active group is used to couple the binding molecule with Compound 1 and Compound 2.

[0020] A "polypeptide" is a polymer comprised of at least two amino acids.

[0021] "Polyethyleneimine substances" are a type of polymer with a main chain of "-CH2CH2NH-", including substances with substitutions on the side chains and / or at both ends.

[0022] "Block" refers to a substance containing two or more basic constituent units of flexible connecting units, such as a block polymer formed by the constituent units of polyoxyethylene ether compounds -OCH2CH2- and the constituent units of polyethyleneimine compounds -CH2CH2NH-.

[0023] The "total degree of polymerization" is the sum of the degrees of polymerization of the two flexible linker units on the first binding molecule and the second binding molecule.

[0024] A "solid phase carrier" is a material whose at least one dimension in the three-dimensional size is greater than 0.1 micron or 0.2 micron, preferably greater than 0.3 micron or 0.5 micron. The material has an adsorption effect or has active functional groups on the surface of the material that can be coupled with binding molecules. The material can be in the following forms: particles, microparticles, metal colloids, fibers, paper, beads, membranes, filter paper, test tubes, microplates, chips, slides, and microarrays, etc.

[0025] Further, the first binding molecule and / or the second binding molecule are antibodies, antigens and / or antigen binding fragments. For example, when the target detection object is an antigen, the first binding molecule and the second binding molecule are optionally antibodies or antibody fragments specific to the antigen; for example, when the target detection object is an antibody, the first binding molecule and / or the second binding antibody are optionally secondary antibodies to the antigen or the anti-target detection antibody.

[0026] The antigen-binding fragment is selected from any one of F(ab)2, F(ab')2, Fab', Fab, Fv and scFv of the antibody.

[0027] Further, the compound 1 is a substance that can catalyze the substrate to produce hydroxyl radicals, including transition metal salts and / or complexes and peroxidases, specific enzymes such as lactoperoxidase, microperoxidase, myeloperoxidase, haloperoxidase, vanadium bromoperoxidase, horseradish peroxidase, fungal peroxidase, lignin peroxidase, peroxidase from Arthromyces ramosus, Mn-dependent peroxidase produced by white rot fungi or soybean peroxidase, transition metal complexes such as ferrous protoporphyrin, etc. can catalyze the chemiluminescent oxidation of substrates. Accordingly, compound 2 is selected from substances that produce photons under the action of the enzyme described in compound 1, such as luminol, isoluminol, rofenine, acridinium ester, lucigenin, 9,10-dihydroacridine and phthaloyl hydrazide.

[0028] Furthermore, the compound 3 in the reagent C is selected from a peroxide compound; for example, hydrogen peroxide, urea peroxide, peracetic acid or perborate; and the pH value of the reagent C is 5.5-9.5, preferably 6.5-8.5.

[0029] It can be understood that, unlike compound 1 catalyzing compound 2 to produce a signal, compound 3 directly reacts with compound 2 to produce a signal. Therefore, at the same concentration, the signal effect produced by the reaction of compound 3 and compound 2 is more obvious than the effect of compound 1 and compound 2. Alternatively, it can be understood that compound 1 has the effect of enhancing the signal production of compound 3 and compound 2.

[0030] "Optical signal" means that the compound generates photons through chemical reactions or is stimulated by the external environment (such as temperature changes, light irradiation, magnetic field changes, etc.). Photons serve as information carriers, and the expected information is obtained by detecting photons, for example, relevant information is obtained by detecting fluorescence, flash or glow.

[0031] Furthermore, the kit also includes reagent D, which contains a solid phase carrier coupled to the connecting structure II, and the connecting structure I and the connecting structure II have specific binding to each other to form a specific binding system; the specific binding system includes: antibody-antigen, avidin-biotin, streptavidin-biotin and Tag-Catcher.

[0032] The working solution concentration of the solid phase carrier complex coupled to the connecting structure II in the reagent D is 0.2-5.0 mg / mL.

[0033] When the connecting structures I and II are antibodies and antigens with characteristic binding, they are different from the types of the detection target and the first binding molecule and / or the second binding molecule, and the antibodies and antigens described in the connecting structures I and II will not produce specific binding with the detection target and the first binding molecule and / or the second binding molecule. Without being limited by the examples, the antibodies and antigens described in the connecting structures I and II can be obtained by means known in the art, for example, if the connecting structure I is fluorescein isothiocyanate (FITC), then the antibody against FITC in the connecting structure II is preferably a monoclonal antibody.

[0034] The "Tag-Catcher" system is composed of two parts, protein and polypeptide (short peptide), and spontaneously forms an isopeptide bond through the residues that can specifically recognize each other with high affinity. It includes the SpyTag-SpyCatcher system, the SdyTag-SdyCatcher system, the SnoopTag-SnoopCatcher system, and the DogTag-DogCatcher system. The binding modes of different "Tag-Catcher" systems are basically the same. The two systems have a high degree of binding and react quickly, and no additional chemical reagents or catalysts are required. For example, the earliest discovered SpyTag-SpyCatcher system, the carboxyl group (aspartic acid residue) of aspartic acid in SpyTag and the primary amino group (lysine residue) of lysine in SpyCatcher specifically recognize each other, and dehydration forms an amide bond. The preparation and principle are shown in References 1 and 2. The preparation and principle of SdyTag-SdyCatcher, SnoopTag-SnoopCatcher and DogTag-DogCatcher are respectively referred to references 3-5. The connection and preparation of Tag-Catcher with magnetic beads, antibodies, proteins and other substances are referred to references 5-10.

[0035] The specific binding of the two parts in the "Tag-Catcher" system is a covalent bond, so after binding, it is less susceptible to environmental changes and the connection is more stable.

[0036] Further, the kit also includes an alkaline solution, the pH value of the alkaline solution is greater than or equal to 8, more preferably greater than or equal to 9, 10, or 11. The alkaline solution can be prepared by a corresponding alkaline substance, such as sodium hydroxide. It is understandable that alkaline substances are commonly used promoters for chemiluminescence, and are particularly suitable for chemiluminescence in enzyme-free systems. For example, after adding hydrogen peroxide to the washed magnetic beads (capturing the analyte), a detectable luminescent signal can be generated after adding an alkaline solution.

[0037] Furthermore, the kit also includes a signal inhibitor (Selective Signal Inhibiting Agent), which can be understood as a signal used to increase the signal of the measurement process. When it is applied to target detection, the degree to which the signal obtained from the measurement reaction system exceeds the background signal is significantly greater than the degree of excess that occurs when there is no signal inhibitor. At the same time, it is necessary to pay attention to that the reagent is basically in an open state during use, and the signal inhibitor will be fully in contact with the air. The signal inhibitor is easily oxidized in the environment, so the stability of the signal inhibitor itself is extremely important.

[0038] The signal inhibitor of the present invention is selected from the types listed in WO2010099486A1, for example, including ascorbic acid or its salts, phenoxazine, 2-aminophenol, 2-amino-p-chlorophenol, 2-amino-o-chlorophenol, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid TROLOXTM, 3-aminotyrosine or a salt thereof, 4-Hydroxy-2-chlorophenol, 4-Hydroxy-2-methoxyphenol, o-Hydroxy-m-chlorophenol, And at least one of the structural compounds shown in Formula 1.

[0039] In addition, WO2010099486A1 disclosed that the signal inhibitors of some structures were less effective. However, the applicant unexpectedly discovered that the compound of the structure shown in Formula 1 has an outstanding effect in suppressing background interference signals, and is particularly remarkable in terms of stability.

[0040]

[0041] Among them, two or three of the substituted R1-R6 are optionally substituted by -OH and / or -NH2, and the remaining substituents are -H, -F, -Cl and / or -Br, and two or three of the substituents are -F, -Cl and / or -Br. Preferably, two of the substituted R1-R6 are substituted by -F, -Cl and / or -Br.

[0042] Therefore, another aspect of the present invention is the use of the signal inhibitor of the present invention in a test kit, specifically for reducing background interference signals.

[0043] The concentration of the signal inhibitor in the detection system of the present invention is 10 -4 mM-10mM, for example 10 -3 mM-1mM or 10 -2 mM-1mM.

[0044] Another aspect of the present invention is to provide a composition for detection, which contains: a substance that can generate hydroxyl free radicals or a substance that generates photons under the action of hydroxyl free radicals, and a binding molecule coupled through a flexible connection unit; optionally, the flexible connection unit is selected from polyoxyethylene ether compounds, polyoxypropylene ether compounds, alkyl groups, polyethylene imine compounds, polypeptides and blocks of the above substance constituent units; the binding molecule also contains at least one connection structure, the binding molecule is a specific binding substance that can specifically bind to the target; and the connection structure does not form a specific connection and the binding molecule is not coupled to a solid phase carrier.

[0045] Furthermore, the binding molecule is an antibody, an antigen and / or an antigen binding fragment.

[0046] Furthermore, the connection structure is selected from any one of the two parts in the following specific binding systems, including: antibody-antigen system, avidin-biotin system, streptavidin-biotin system and Tag-Catcher system.

[0047] The antibody-antigen system and the Tag-Catcher system have the functions and types of selections as described above.

[0048] Furthermore, the substance that can generate hydroxyl free radicals includes horseradish peroxidase, and the compound that generates photons under the action of hydroxyl free radicals includes at least one of luminol, isoluminol, rofenine, acridinium ester, lucigenin, 9,10-dihydroacridine and phthaloyl hydrazide and their derivatives.

[0049] Another aspect of the present invention is to provide the use of the above-mentioned composition in the preparation of a detection product; the product is used for the detection of blood, urine, bone marrow, cerebrospinal fluid, pleural effusion, ascites, pericardial fluid, joint fluid, hydrocele, bile and / or tissue samples; preferably blood, plasma, serum and urine samples; further, the product is a kit.

[0050] Another aspect of the present invention is to provide a judgment-type detection method, comprising the following steps:

[0051] S1: Perform interference identification on the sample to be tested and obtain the interference value;

[0052] S2: Compare the interference value with a preset threshold value, and select to execute steps S3A-S4A or S3B-S4B according to the comparison result;

[0053] in,

[0054] Step S3A includes: selecting a reagent and reacting the sample to be tested with the reagent without a solid phase carrier;

[0055] Step S3B includes: selecting reagents and reacting the sample to be tested with the reagent containing the solid phase carrier, and separating impurities in the detection system;

[0056] Steps S4A and S4B include: measuring the reaction system and reporting the test results.

[0057] It is understandable that due to the differences in detection methods, the reagents used in S3A and S3B are also different. For example, the reagents in step S3A include reagent A, reagent B, and reagent C, and the reagents in step S3B include reagent A, reagent B, reagent C, reagent D, a cleaning agent, and an alkaline solution; at the same time, the reagents in S3A and S3B optionally contain a signal inhibitor. In the absence of mutual influence, the above reagents can be stored separately or as a mixture.

[0058] Furthermore, before step S1, the following step S0 is also included: comparing and judging the test item of the test sample with the preset item; and selecting to execute S1 and subsequent steps or steps S3B-S4B (such as Figure 2 shown).

[0059] Therefore, the present invention also relates to a detection method, which comprises:

[0060] S0: Compare and judge the test items of the sample to be tested with the preset items; and select to execute (i) or (ii) test process according to the comparison and judgment results;

[0061] The (i) detection process comprises:

[0062] S1: Perform interference identification on the sample to be tested and obtain the interference value;

[0063] S2: Compare the interference value with the preset threshold, and select to execute S3A-S4A steps or S3B-S4B steps according to the comparison result; wherein,

[0064] Step S3A includes: selecting a reagent and reacting the sample to be tested with the reagent without a solid phase carrier;

[0065] Step S3B includes: selecting reagents and reacting the sample to be tested with the reagent containing the solid phase carrier, and separating impurities in the detection system;

[0066] Steps S4A and S4B include: measuring the reaction system and reporting the test results;

[0067] The (ii) detection process comprises:

[0068] Step S3B includes: selecting reagents and reacting the sample to be tested with the reagent containing the solid phase carrier, and separating impurities in the detection system;

[0069] The S4B step includes: measuring the reaction system and reporting the test results.

[0070] The reagents of step S3A include reagent A, reagent B and reagent C; the reagents of step S3B include reagent A, reagent B, reagent C, reagent D and cleaning solution; further, the reagents of step S3A and / or step S3B also include signal inhibitors, and the reagents A, reagent B, reagent C, reagent D and signal inhibitors have the selected types described in this article.

[0071] The "items to be tested" are items to be tested for the sample to be tested, the purpose of which is to obtain quantitative information of a certain or certain biochemical substances, and the "preset items" are pre-set test items. The purpose of setting the "preset items" is to reduce interference and provide detection accuracy. "Preset items" can be determined, for example, based on clinical research or literature. Since the content of the target to be detected in the sample is extremely low or there is great interference and it is impossible to accurately quantify the analysis, this type of test item can be regarded as a "preset item". When the "items to be tested" are "preset items" or include "preset items", it is necessary to adopt a detection step to eliminate interference, such as using S3B-S4B steps; when the "items to be tested" do not include "preset items", otherwise S1 and subsequent steps are adopted; or because the content of the target to be detected in the sample is extremely low or there is great interference and it is impossible to accurately quantify the analysis, the test items that are not such cases are set as "preset items", and when the "items to be tested" meet the "preset items", S1 and subsequent steps are adopted, otherwise S3B-S4B steps are adopted. For example, the content of AD markers (such as tau-181) in the blood is low, and the detection item for tau-181 in the blood sample is set to a "preset item". When the "item to be tested" is to detect tau-181 in the blood sample, it is judged to meet the "preset item" and the S3B-S4B steps are used.

[0072] Furthermore, the relationship between the interference value and the preset threshold is determined by one or more of the following methods:

[0073] 1) Using a light source to illuminate the sample to be tested or a mixed solution of the sample to be tested and a reagent, detecting the transmitted light and / or scattered light signal, and making a judgment by comparing the transmitted light and / or scattered light signal with a preset threshold;

[0074] 2) Semi-quantitatively give the serum / plasma sample value by calculating the difference in absorbance of the diluted sample under dual wavelengths, and compare and determine with the preset threshold; the sample value is, for example, the value of lipemia, hemolysis and / or icterus in the sample;

[0075] 3) Compare the color features of the sample image with the preset threshold.

[0076] The "mixed solution of the sample to be tested and the reagent" refers to a solution obtained by mixing the original sample with the reagent that can enhance the detection effect.

[0077] Without limitation to the examples, the above methods for determining whether a sample has an interference value all adopt means known in the art, such as using the methods and modules described in CN105980833B and CN113592842B to detect lipemia, hemolysis and icteric blood samples, and for example, using the methods and instruments described in literature or commercial products such as CN109374551A, CN204101456U, CN210894370U, or EXC400 automatic biochemical analyzer (Zhongyuan Huiji Biotechnology Co., Ltd.) to detect sample transmitted light and / or scattered light signals, using UV-4800 dual-beam spectrophotometer (Unico (Shanghai) Instrument Co., Ltd.) for dual-wavelength detection, and obtaining images by means of ordinary cameras or miniature cameras.

[0078] The "preset threshold" is a value set based on existing information and data, which has the function of distinguishing high-interference samples from low-interference samples. The information and data required to set the "preset threshold" can be obtained from, for example, the difference between special samples and ordinary samples analyzed by clinical big data. For example, due to the hemolysis of red blood cells, there is a significant difference in the transmitted light between the two blood samples (relative to non-hemolysis samples), such as the lower transmittance of hemolysis samples. Based on the big data, the transmittance value range of ordinary blood samples is obtained, and the "preset threshold" is set accordingly. The "preset threshold" can be appropriately and strictly provided to ensure the accuracy of the test results. For example, in order to reduce the interference of hemolysis samples, the "preset threshold" of transmitted light can be 5% or 10% lower than the transmittance value of ordinary blood samples. When the transmittance of the test sample is lower than the "preset threshold", it is judged as a "high-interference" sample; when the transmittance of the test sample is higher than the "preset threshold", it is judged as a "low-interference" sample.

[0079] To further improve the detection accuracy, preferably, there may be multiple "preset thresholds" in step S1, which are obtained by measuring under different detection methods. When the measured value of the test sample meets the low interference identification conditions compared with the two "preset thresholds", the sample will be identified as low interference, otherwise it will be identified as high interference. For example, two different "preset thresholds" are determined by transmission method and dual-wavelength measurement, and the detection sample also adopts transmission method and dual-wavelength detection sample. When the difference between the transmittance and absorbance of the test sample is higher than the "preset threshold" set by the transmission method and lower than the "preset threshold" set by the dual-wavelength measurement method, the sample is identified as a low-interference sample.

[0080] The purpose of "separating impurities" or "removing impurities" in the present invention is to reduce the content of substances in the reaction system that interfere with the measurement results. The interference with the measurement results may be, for example, increasing the background signal, suppressing the output of photons of the luminescent compound, reducing the detection amount of the expected signal, etc., and substances that can produce the above effects can be regarded as impurities. The methods of separating and removing impurities, such as washing, centrifugation, sedimentation, adsorption (such as HPLC, chromatography column, etc.), liquid separation, etc., are not limited to the examples. Any method that reduces the content of impurities in the measurement system and reduces its influence on the measurement system can be regarded as an effective method of "separating impurities".

[0081] Furthermore, according to preset items or interference judgments, the "impurity separation" step can be performed multiple times, such as twice or more; further, the cleaning method with a solid phase carrier is a preferred impurity separation method.

[0082] Furthermore, the reagents used in the detection method described in the present invention have the reagents of the composition described in the above-mentioned kit, or the kit described in the present invention is used in conjunction with the detection method described in the present invention for the detection of the target detection object.

[0083] Another aspect of the present invention is to provide a multi-level judgment detection system, which includes a detection item comparison module, an interference identification and analysis module, an impurity separation module, a reagent absorption module, an optical detection module, a signal processing module, etc.

[0084] The comparison module is used to compare the item to be tested with the preset item information;

[0085] The interference identification and analysis module is used to analyze sample interference information;

[0086] The impurity separation module is used to separate impurities and reduce substances in the detection system that affect the detection results; further, the impurity separation module includes a cleaning submodule, which uses the difference between the reagent bound to the solid phase carrier and the reagent not bound to the solid phase carrier to separate the impurity substances, and the difference is manifested as: the difference in the magnetic field, the difference under the action of centrifugal force, the difference under the action of gravity, the difference under the action of buoyancy, the difference in solubility or the difference in retention time in the chromatography column.

[0087] The optical testing module is used to detect the signal generated by the reaction system;

[0088] The signal processing module is used to process signals and convert the signals into visual information, such as pictures or numbers.

[0089] The detection system may have at least two different detection channels for detecting high-interference samples and low-interference samples respectively. Therefore, based on this situation, the detection system also includes a sample transfer module, which transfers the sample to different detection channels based on the interference identification result.

[0090] Alternatively, the detection system may have only one detection channel, and high-interference samples and low-interference samples are detected in the same detection channel by absorbing different reagents through a reagent absorption module.

[0091] Furthermore, whether to call the impurity separation module is determined according to the analysis result of the interference identification and analysis module.

[0092] In addition, based on the need for impurity separation, the detection system also includes a module for transferring samples before and after impurity separation. This module can be the aforementioned sample transfer module or a separate module.

[0093] In the present invention, the biological sample containing the target detection object can exist in any form. The technical solution of the present invention is particularly suitable for samples that are prone to produce high interference values, such as blood, plasma, serum and urine.

[0094] The "kit" of the present invention is based on reagent A and reagent B, and optionally contains reagent C, reagent D and / or signal inhibitor and other reagents according to detection requirements.

[0095] In the present invention, "test kit" refers to a detection system composed of detection reagents. Different detection reagents can be stored in the same packaging container, or stored separately in containers, or some reagents can be mixed and stored in containers, and other reagents can be stored separately in containers. The containers storing different reagents can be connected together, or partially connected together, or not connected together at all. For example, according to factors such as system control and equipment, the reagent detection system includes reagent A, reagent B and reagent D, and reagent A, reagent B and reagent D are stored separately and taken as needed during detection; or for example, the reagent detection system includes reagent A, reagent B, reagent C and reagent D, and reagent A and reagent C are stored in one container, and reagent B and reagent D are stored separately, and are taken as needed during detection.

[0096] In the present invention, "specific binding" has the commonly known meaning in the art, which is a biological binding process in which a certain ligand that can be competitively blocked by corresponding substances interacts with a specific structural site in vitro or in vivo, such as the binding between antigen and antibody or receptor and ligand, the binding between biotin and avidin, etc.

[0097] In the present invention, the "coupling" method includes two parts of the substance being directly connected through an active functional group (direct coupling), or being indirectly connected through one or two or more substances (indirect coupling). A direct coupling method, for example, is the connection between a solid phase carrier with a carboxyl group on the surface and the amino portion of an antibody, thereby directly coupling the solid phase carrier to the antibody. An indirect coupling method, for example, is the connection of the two parts through a secondary antibody or through avidin-biotin.

[0098] The kit and the detection composition thereof of the present invention can be applied to the detection of both high-interference samples and common samples. Different reagents in the kit are selected to detect the samples according to the difference of the samples, thereby meeting the needs of high-throughput detection and the accuracy of the results.

[0099] For example, in one embodiment of the present invention, the kit includes:

[0100] 1) Reagent A: containing a first binding molecule coupled with compound 1;

[0101] 2) Reagent B: containing a second binding molecule coupled with compound 2;

[0102] 3) Reagent D: containing a solid phase carrier coupled to the connecting structure II;

[0103] The first binding molecule or the second binding molecule includes at least one connection structure I, and the connection structures I and II have specific binding effects. The detection principle is: judge the sample interference value. If it is a low-interference sample, the first binding molecule in reagent A and the second binding molecule in reagent B are directly used to capture the target object to be detected (such as an antigen), and compound 2 generates a light signal under the catalytic action of compound 1, and completes the detection; if it is a high-interference sample, the solid phase carrier in reagent D is used to separate the first binding molecule and the second binding molecule that capture the target detection object from the reaction system, and then perform subsequent detection, thereby reducing interference and improving detection accuracy. The first binding molecule, the second binding molecule, compound 1, compound 2, connection structures I and II are consistent with the previous description.

[0104] For example, in another embodiment of the present invention, the kit includes:

[0105] 1) Reagent A: contains the first binding molecule;

[0106] 2) Reagent B: containing a second binding molecule coupled with compound 2;

[0107] 3) Reagent C: containing compound 3;

[0108] 4) Reagent D: containing a solid phase carrier coupled to the connecting structure II;

[0109] The first binding molecule and / or the second binding molecule include at least one connection structure I, and the connection structures I and II have specific binding effects. The detection principle is: judge the sample interference value. If it is a low-interference sample, the first binding molecule in reagent A and the second binding molecule in reagent B are directly used to capture the target to be detected (such as an antigen), and compound 2 reacts with compound 3 in reagent C to generate a light signal and complete the detection; if it is a high-interference sample, the solid phase carrier in reagent D is used to separate the first binding molecule and the second binding molecule that capture the target detection object from the reaction system, and then perform subsequent detection, thereby reducing interference and improving detection accuracy. The first binding molecule, the second binding molecule, compound 2, compound 3, connection structures I and II are consistent with the previous description.

[0110] For example, in another embodiment of the present invention, the kit includes:

[0111] 1) Reagent A: containing a first binding molecule coupled with compound 1;

[0112] 2) Reagent B: containing a second binding molecule coupled with compound 2;

[0113] 3) Reagent C: containing compound 3;

[0114] 4) Reagent D: containing a solid phase carrier coupled to the connecting structure II;

[0115] The first binding molecule and / or the second binding molecule include at least one connection structure I, and the connection structures I and II have specific binding effects. The detection principle is: judge the sample interference value. If it is a low-interference sample, the first binding molecule in reagent A and the second binding molecule in reagent B are directly used to capture the target to be detected (such as an antigen), and compound 1 catalyzes the reaction of compound 2 with compound 3 in reagent C to produce a light signal, and complete the detection; if it is a high-interference sample, the solid phase carrier in reagent D is used to separate the first binding molecule and the second binding molecule that capture the target detection object from the reaction system, and then perform subsequent detection, thereby reducing interference and improving detection accuracy. The first binding molecule, the second binding molecule, compound 1, compound 2, compound 3, connection structures I and II are consistent with the previous description.

[0116] Optionally, the above-mentioned embodiments further include a signal inhibitor, and when a reagent with a solid phase carrier is used, a washing solution is also included.

[0117] refer to Figure 1 , Figure 1 This is a schematic diagram of a detection implementation method of the present invention. The composition of the kit is different depending on the high-interference sample and the low-interference sample.

[0118] refer to Figure 2 , Figure 2This is a flow chart of an implementation method of a detection method described in the present invention. Preset items are first set in the detection system. When the preset items and the items to be tested are judged in step S0 and the items to be tested do not meet the content of the preset items, the sample interference value is identified in step S1 to obtain the interference value. In step S2, the interference value is compared with the preset threshold value. For samples with low interference as a comparison result, a reagent without a solid phase is used and reacted in step S3A, and a signal generated in the reaction process is detected in step S4A and a report on the corresponding results is output; for samples with high interference as a comparison result, a reagent containing a solid phase is used and reacted as well as impurity removal and separation is performed in step S3B, and a signal generated in the reaction process is detected in step S4B and a report on the corresponding results is output.

[0119] When the detection item does not meet the preset item content, a reagent containing a solid phase is used in step S3B to carry out a reaction and remove impurities, and a signal generated during the reaction process is detected in step S4B and a report of the corresponding result is output.

[0120] refer to Figure 3 , Figure 3 It is a schematic diagram of an implementation of a detection system according to the present invention, comprising a comparison module S10, an interference identification and analysis module S20, an impurity separation module S30, a reagent aspiration module S40, an optical detection module S50, and a signal processing module S60.

[0121] Based on the technical solution of the present invention, the inventors believe that the beneficial effects of the present invention are at least:

[0122] 1) A test reagent with a completely new structure is proposed. The test reagent contains a structure connected to a solid phase carrier. According to the sample test needs, the test reagent is used in combination with the solid phase carrier containing the connection structure during the test process. It is flexible to use and can meet different detection needs.

[0123] 2) The kit described in the present invention contains a variety of reagents, and different types of reagents can be mixed according to different sample detection requirements. It integrates the advantages of solid phase cleaning detection technology and homogeneous detection technology, which not only avoids unnecessary cleaning when the whole sample is detected in solid phase mode, but also avoids the problem of low accuracy due to the presence of special samples when the whole sample is detected in homogeneous mode.

[0124] 3) The kit of the present invention has a wider range of application scenarios and can be applied to the detection needs of various types of samples, meeting the requirements of complex application scenarios and significantly improving the reliability of the kit.

[0125] 4) The detection method and detection system described in the present invention have multi-level judgment steps and corresponding modules. Different modules are selected according to different judgment results. The detection method is more flexible and more suitable for the detection of sample groups containing complex situations. The detection time under high-throughput detection is shorter than that of solid-phase detection, and the detection accuracy is higher than that of full homogeneous detection.

[0126] 5) A new class of signal inhibitors suitable for homogeneous reactions is proposed, which has higher stability in practical application scenarios.

[0127] References:

[0128] Document 1: Zakeri, B. & Howarth, M. Spontaneous Intermolecular Amide BondFormation between Side Chains for Irreversible PeptideTargeting. J. Am. Chem. Soc. 132, 4526–4527 (2010);

[0129] Document 2: Zakeri, B. et al. Peptide tag forming a rapid covalent bond to aprotein, through engineering abacterial adhesin. Proc. Natl. Acad. Sci. USA2012, 109, E690–E697;

[0130] Document 3: Tan LL, et al.Kinetic Controlled Tag-Catcher Interactions for Directed Covalent Protein Assembly.PLoS ONE 11(10):e0165074;

[0131] Document 4: Veggiani G, et al, Programmable polyproteams built using twinpeptide superglues. Proc NatlAcad Sci US A. 2016 Feb 2; 113(5): 1202-7;

[0132] Document 5: Anthony H. Keeble, et al, DogCatcher allows loop-friendly protein-protein ligation, Cell Chem Bio, 29(2), P339-350.E10, DOI: https: / / doi.org / 10.1016 / j.chembiol.2021.07.005;

[0133] Document 6: X.Pei, et al, Putting precision and elegance in enzyme immobilization with bio-orthogonal chemistry, Chem.Soc.Rev., 2022, 51, 7281, DOI: 10.1039 / D1CS01004B;

[0134] Document 7: CN117723749A;

[0135] Reference 8: CN114990146A;

[0136] Reference 9: CN117362447A;

[0137] Document 10: CN116444623B.

[0138] Instruction Manual

[0139] Figure 1 A detection schematic diagram of the present invention.

[0140] Figure 2 A schematic flow chart of a detection method adopted by the present invention.

[0141] Figure 3 A schematic diagram of a detection system adopted by the present invention. DETAILED DESCRIPTION

[0142] The present invention is further explained in conjunction with specific examples. If no specific technology or conditions are specified in this example, the operation is carried out according to the conventional technical methods and instrument instructions in the art. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased from the market or self-developed, and the relevant antibodies are all self-developed by Chongqing Aishengsi Bioengineering Co., Ltd.

[0143] Example 1: Preparation of raw materials

[0144] Reagent A:

[0145] Weigh 5 mg HRP and dissolve it in 1 ml distilled water; add 0.2 ml of freshly prepared 0.1 M NaIO 4 solution, stir at room temperature in the dark for 20 minutes; put the above solution into a dialysis bag and dialyze against 1 mM sodium acetate buffer at pH 4.4 at 4°C overnight; add 20 μl of 0.2 M pH 9.5 carbonate buffer to raise the pH of the above aldehyded HRP to 9.3, and then immediately add 10 mg IgG (thyroid stimulating hormone (TSH) monoclonal antibody) in 1 ml 0.01 M carbonate buffer, gently stir at room temperature in the dark for 2 hours; add 0.1 ml of freshly prepared 4 mg / ml NaBH4 solution, mix well, and let stand at 4°C for 2 hours; put the above solution into a dialysis bag and dialyze against 0.15 M pH 7.4 After PBS dialyzing to remove ammonium ions (detected with Nessler's reagent), centrifuge at 10,000 r / min for 30 min to remove the precipitate. The supernatant is the enzyme conjugate. After the concentration is determined, add an equal amount of 60% glycerol to aliquot and store at 4°C. Before aliquoting, add BSA at a ratio of 10 mg / ml as a stabilizing protective agent.

[0146] Reagent B-1:

[0147] 5 mg of TSH antibody was weighed, desalted using a PD-10 desalting column, eluted with 2.5 ml of biotin coupling buffer (50 mM triethanolamine, pH 8.4), and then diluted to 1 mg / mL with biotin buffer A. 10 mg NHS-Biotin and NHS-acridine compounds were fully dissolved in DMSO to 3.0 mg / ml. According to the ratio of antibody: NHS-Biotin: NHS-acridine compound = 1:20:20 (molar ratio), NHS-Biotin and NHS-acridine compound solutions were added to the above antibody solution and placed at 25°C (the allowable error range is ±2°C) for 180 minutes. The solution after the reaction was desalted with a PD-10 desalting column to remove molecules that did not participate in the reaction, eluted with 2.5 ml of biotin coupling buffer B, and stored at 4°C after measuring the concentration using a UV spectrophotometer. BSA was added as a stabilizing protective agent at a ratio of 10 mg / ml before packaging.

[0148] Reagent B-2:

[0149] 5 mg of TSH antibody was weighed, desalted using a PD-10 desalting column, eluted with 2.5 ml of biotin coupling buffer A, and then diluted to 1 mg / mL with biotin buffer (50 mM triethanolamine, pH 8.4). 10 mg of NHS-Biotin and NHS-(PEG) were weighed separately. 24-Acridine compound, fully dissolved in DMSO to 3.0 mg / ml, according to the antibody: NHS-Biotin: NHS-(PEG) 24 -Acridine compound = 1:20:20 (molar ratio), weigh NHS-Biotin and NHS-(PEG) 24 -Acridine compound solution was added to the above antibody solution and placed at 25°C (allowable error range is ±2°C) for 180 minutes. The solution after the reaction was desalted with a PD-10 desalting column to remove molecules not involved in the reaction, and eluted with 2.5ml biotin coupling buffer (50mM triethanolamine, pH8.4)). The concentration was measured using an ultraviolet spectrophotometer and then frozen at 4°C or -20°C. BSA was added as a stabilizing protective agent at a ratio of 10mg / ml before packaging.

[0150] Reagent B-3:

[0151] 5 mg of TSH antibody was weighed, desalted using a PD-10 desalting column, and eluted with 2.5 ml of biotin coupling buffer A, and then the antibody was diluted to 1 mg / mL with biotin buffer (50 mM triethanolamine, pH 8.4). 10 mg of NHS-Biotin and NHS-(L-Lysine) were weighed separately. 11 -Acridine compound, fully dissolved in DMSO to 3.0 mg / ml, according to the antibody: NHS-Biotin: NHS-(L-Lysine) 11 -Acridine compound = 1:20:22 (molar ratio), weigh NHS-Biotin and NHS-(L-Lysine) 11 -Acridine compound solution was added to the above antibody solution and placed at 28°C (allowable error range is ±2°C) for 150 minutes. The solution after the reaction was desalted with a PD-10 desalting column to remove molecules not involved in the reaction, and eluted with 2.5ml biotin coupling buffer (50mM triethanolamine, pH8.4)). The concentration was measured using a UV spectrophotometer and then frozen at 4°C or -20°C. BSA was added as a stabilizing protective agent at a ratio of 10mg / ml before packaging.

[0152] Reagent C:

[0153] Hydrogen peroxide was dissolved in TBS buffer (pH ≈ 8), wherein the final concentration of hydrogen peroxide was 0.1 M and the final concentration of TBS was 10 mM.

[0154] Reagent D:

[0155] The streptavidin-coated magnetic beads with a diameter of 2.8 μm purchased from Thermo were washed and diluted to 1 mg / mL for use.

[0156] Alkaline solution:

[0157] The solution was adjusted to pH 12 using sodium hydroxide.

[0158] Washing solution: 500 mM PBS buffer, 10% sodium ion, 0.7% EDTA-2Na, 0.5% SDS, 1% Tween 20, 0.1% sodium azide, 0.1% defoaming agent, pH about 7.

[0159] Example 2: Evaluation of signaling inhibitors

[0160] The effect of the signal inhibitor was evaluated from two aspects: signal inhibitor stability and elimination of background interference. The prepared signal inhibitor solution was placed in a test tube and exposed to air for 0min, 5min and 20min before the luminescence signal test was performed. The signal-to-noise ratio S / N (positive sample signal / negative sample signal) was used as an indicator. The higher the ratio, the better the effect.

[0161] Test steps: first prepare a test positive serum sample with a TSH antigen concentration of 5.0 μIU / mL, add 60 μl of reagent A and reagent B-1 in Example 1 to 20 μl of the test positive serum sample, mix well and react at 37 degrees Celsius for 10 minutes, then add 85 μl of reagent C and 6 μl of a signal inhibitor with a concentration of 0.1 mM, and the light signal generated by the addition is captured by a photomultiplier tube, and then the intensity of the light signal is quantified; the antigen concentration of the negative serum sample is 0, and other reagents remain the same. The test information and results are shown in Table 1.

[0162] Table 1 Test results of different substances

[0163]

[0164]

[0165] It can be seen from Table 1 that the effectiveness of signal inhibitors such as vitamin C is consistent with WO2010099486A1. However, the influence of air on signal inhibitors is difficult to avoid. Considering storage and actual use, the signal inhibitor can be selected as a substance in which two or three substituents in R1-R6 of the substituted benzene ring are -OH and / or -NH2, respectively, and the remaining substituents are -H, -F, -Cl and / or -Br, respectively, and two or three substituents are -F, -Cl and / or -Br, respectively. Preferably, two of the substituted R1-R6 are -F, -Cl and / or -Br, respectively, and more preferably the substituent is Cl.

[0166] Example 3: Effect of reagent composition on signal

[0167] In order to prove the differences in the detection results of reagents with different compositions and structures, the performance of reagents with different compositions and structures in signal output can be intuitively understood by detecting the signal and signal-to-noise ratio.

[0168] The reagents prepared in Implementation 1 were prepared into a kit and their performance was tested. Kit 1 includes reagent A, reagent B-2, reagent C and the signal inhibitor 14 in Table 1 (contact with air for 20 minutes); Kit 2 includes reagent A, reagent B-3 and the signal inhibitor 14 in Table 1 (contact with air for 20 minutes), reagent C; Kit 3 includes reagent A, reagent B-3, reagent C, reagent D, the signal inhibitor 14 in Table 1 (contact with air for 20 minutes), alkaline solution and cleaning solution, and the concentrations of reagents A, B and C in kits 1-3 are kept consistent. Samples containing different TSH concentrations were prepared by adding TSH to the buffer and collecting clinical serum samples with three concentrations of low, medium and high. The antigen concentration of each sample is shown in Table 2. The performance of kits 1-3 was analyzed using the following reaction mode.

[0169] Reaction mode of kits 1 and 2: Take 20μl of each sample, add 60μl of reagent A and reagent B to each sample, mix well, react at 37 degrees Celsius for 10 minutes, then add 85μl of reagent C and 6μl of signal inhibitor with a concentration of 0.1mM. The generated light signal is captured by a photomultiplier tube, and the intensity of the light signal is quantified.

[0170] Reaction mode of kit 3: Take 20μl of each sample, add 60μl of reagent A and reagent B, and 30μl of reagent D to each sample, mix well, and react at 37 degrees Celsius for 10 minutes. After 3 steps of magnetic separation and washing, add 85ul of reagent C, 6μl of signal inhibitor with a concentration of 0.1mM and an appropriate amount of alkaline solution. The generated light signal is captured by a photomultiplier tube, and the intensity of the light signal is quantified.

[0171] Table 2 Test results of different kit compositions

[0172]

[0173] * Antigen concentration in serum samples was determined using a commercially available kit (electrochemiluminescence method, Roche Diagnostics GmbH)

[0174] As can be seen from Table 2, since the luminescent substrates in kits 1 and 2 are connected by flexible units, the steric hindrance is smaller, and the signal is higher (not listed) than that of the reagent without flexible connection units in Example 2, and the signal-to-noise ratio is also higher. Due to the absence of a washing step, the signal values ​​of kits 1 and 2 are higher than those of kit 3. Although the signal value of kit 3 is slightly lower, it has a higher signal-to-noise ratio, mainly because the background value is lower after washing. It can be seen from the above verification that the flexible unit connection helps to improve the luminescent signal and signal-to-noise ratio, and the washing step can significantly improve the signal-to-noise ratio.

[0175] Example 4 Effect of reagent composition and detection strategy selection

[0176] In order to further demonstrate the beneficial effects of the multi-stage judgment detection method of the present invention, the detection time (efficiency) and detection accuracy of different detection strategies were measured.

[0177] (1) Sample setting for time detection

[0178] First, TSH was added to the buffer to prepare a basic sample with a TSH concentration of 0.05 μIU / mL. Two 100 mL basic samples were taken, and 1 ml of TBS buffer (pH 8.0) and 1 ml of red dye solution prepared by the buffer were added to the two basic samples, respectively, and recorded as the experimental group and the interference group. The experimental group and the interference group formed a test sample group. By controlling the number of interference groups in the number of test samples, sample groups of different situations were formed, and different detection strategies were used to detect different sample groups in turn, and the time differences used under different strategies were determined. The results are shown in Table 4.

[0179] (2) Sample setting for accuracy test

[0180] TSH was added to the buffer to prepare samples with different concentrations (prepared samples) and clinical serum samples with three antigen concentrations of low, medium and high were collected. Four samples of each antigen concentration were taken, each 200 μL, one of which was recorded as the experimental group, and hemoglobin (prepared to a final concentration of 10 mg / dL), bilirubin (prepared to a final concentration of 5 mg / dL) and lipid (prepared to a final concentration of 1000 mg / dL) were added to the remaining three samples, which were recorded as the hemolysis group, jaundice group and lipemia group, respectively. The information of each sample is shown in Table 3, and the test results are shown in Table 5.

[0181] Table 3 Sample information for accuracy analysis

[0182]

[0183] *Antigen concentration in serum samples was determined by commercially available kit (electrochemiluminescence method, Roche Diagnostics GmbH); **Intralipid, provided by Sigma

[0184] (3) Construction of solid phase method for sample determination

[0185] The method comprises the following steps: taking 20 μl of a sample, adding 60 μl of each of the reagent A and reagent B-1 in Example 1 and 30 μl of the reagent D to the sample, mixing well and reacting at 37° C. for 10 minutes, performing 3 steps of magnetic separation and washing, and then adding 85 μl of the reagent C and an appropriate amount of alkaline solution. The generated light signal is captured by a photomultiplier tube, and the light value signal is converted into a concentration value through a calibration curve.

[0186] (4) Construction using homogeneous detection method

[0187] The method comprises the following steps: taking 20 μl of the test sample, adding 60 μl of reagent A and reagent B-1 in Example 1 to the sample, mixing well and reacting at 37° C. for 10 min, then adding 85 μl of reagent C and 6 μl of 0.05 mM test substance 10 in Table 1, and capturing the generated light signal by a photomultiplier tube, and converting the light value signal into a concentration value through a calibration curve.

[0188] (5) Technical detection method of the present invention

[0189] The following steps are involved:

[0190] A. Set the preset item to "NT-proBNP". After the comparison module determines, the test item "TSH" does not meet the preset item;

[0191] B. Measure the transmittance of three normal samples (serum samples with an antigen of 2.44 μIU / mL) at a wavelength of 500 nm, and take 95% of the average transmittance value as the "preset threshold";

[0192] C. Measure the transmittance of samples that do not meet the "preset items" and make interference value judgments. If the transmittance is higher than or equal to the "preset threshold", it is judged as a low-interference sample; if the transmittance is lower than the "preset threshold", it is judged as a high-interference sample;

[0193] D. For high-interference samples, the above-mentioned "solid phase method" is used for detection; for low-interference samples, the above-mentioned "homogeneous detection" is used for detection.

[0194] (6) Results

[0195] According to Table 4, it can be seen from the detection time of a single sample that, compared with homogeneous detection, the detection time of the solid phase detection method is significantly increased due to the addition of the cleaning step. Taking the daily sample detection processing volume of 800 samples in a medium-sized hospital as an example, the detection time of the solid phase detection mode is more than twice that of the homogeneous detection mode. In the presence of normal interfering samples (10%), the detection time of the method described in the present invention is increased by 18% and reduced by 44% respectively relative to the complete homogeneous mode and the complete solid phase mode. Even if abnormal samples appear on a large scale (25%), the detection time is increased by about 43% and reduced by 33% relative to the complete homogeneous mode and the complete solid phase mode.

[0196] It can be seen that the detection method of the present invention has a higher detection efficiency than that of a solid phase detection mode, reduces unnecessary cleaning of samples entering the cleaning stage, and will also significantly save detection costs, outputting more accurate detection results at a lower cost. It should be understood by those skilled in the art that based on the above-mentioned verification process, when the sample detection amount is further increased, the detection method of the present invention will have more obvious advantages in efficiency and cost.

[0197] Table 4 Detection efficiency of different detection strategies

[0198]

[0199] From the results in Table 5, it can be seen that the multi-stage judgment detection method of the present invention is basically equivalent to the detection method that completely adopts the solid phase in terms of detection accuracy. However, since the detection method of the present invention has the ability to identify interfering samples, its detection accuracy is significantly improved compared with the detection method that completely adopts the homogeneous mode.

[0200] Combined with the results shown in Table 4 and Table 5, the multi-level judgment detection method of the present invention has accurate recognition capability for interference samples, higher detection efficiency, lower detection cost and higher accuracy. The detection method of the present invention is particularly suitable for high-throughput detection needs.

[0201] Table 5 Detection accuracy of different detection strategies

[0202]

[0203]

[0204] Example 5: Determination of NT-proBNP

[0205] NT-proBNP is the best laboratory test indicator for evaluating heart failure, but its content in blood samples is extremely low. The detection of this type of substance has extremely high requirements on the detection method and detection reagent. Taking NT-proBNP detection as an example, the universality, sensitivity and accuracy of the detection method and detection reagent of the present invention are demonstrated.

[0206] (1) Raw material preparation:

[0207] Reagent A:

[0208] Weigh 5 mg HRP and dissolve it in 1 ml distilled water; add 0.2 ml of freshly prepared 0.1 M NaIO 4 solution and stir at room temperature in the dark for 20 minutes; put the above solution into a dialysis bag and dialyze against 1 mM sodium acetate buffer at pH 4.4 at 4°C overnight; add 20 μl of 0.2 M pH 9.5 carbonate buffer to raise the pH of the above aldehyde-modified HRP to 9.3, and then immediately add 10 mg IgG (NT-proBNP monoclonal antibody) in 1 ml of 0.01 M carbonate buffer and gently stir at room temperature in the dark for 2 hours; add 0.1 ml of freshly prepared 4 mg / ml NaBH4 solution, mix well, and place at 4℃ for 2 hours; put the above solution into a dialysis bag, dialyze against 0.15MpH7.4PBS, remove ammonium ions (detected by Nessler's reagent), centrifuge at 10000r / min for 30min to remove the precipitate, the supernatant is the enzyme conjugate, after measuring the concentration, add an equal amount of 60% glycerol to aliquot and store at 4℃. Before aliquoting, add BSA at a ratio of 10mg / ml as a stabilizing protective agent.

[0209] Reagent B:

[0210] 5 mg of NT-proBNP antibody (NT-proBNP monoclonal antibody, Chongqing Aishengsi Bioengineering Co., Ltd.) was weighed, desalted using a PD-10 desalting column, eluted with 2.5 ml of biotin coupling buffer A, and then diluted to 1 mg / mL with biotin buffer A. 10 mg NHS-Biotin and NHS-(PEI) 20 -Acridine compound, fully dissolved in DMSO to 3.0 mg / ml, according to the antibody: NHS-Biotin: NHS-(PEI) 20 - acridine compound = 1:20:20 (molar ratio), weigh NHS-Biotin and NHS-(PEI) 20- Add the acridine compound solution to the above antibody solution and place it at 25°C (with an allowable error range of ±2°C) for 180 minutes. The solution after the reaction was desalted with a PD-10 desalting column to remove molecules that did not participate in the reaction, eluted with 2.5ml biotin coupling buffer B, and stored at 4°C after measuring the concentration using a UV spectrophotometer. BSA was added as a stabilizing protective agent at a ratio of 10mg / ml before packaging.

[0211] Reagent C, reagent D, alkaline solution and cleaning solution are the same as those in Example 1.

[0212] (2) Sample construction

[0213] Samples containing different concentrations were prepared by adding NT-proBNP to the buffer (prepared samples) and clinical serum samples of two concentrations were collected. Four samples of each concentration were taken, each 200 μL, one of which was recorded as the experimental group, and hemoglobin (prepared to a final concentration of 10 mg / dL), bilirubin (prepared to a final concentration of 5 mg / dL) and lipin (prepared to a final concentration of 1000 mg / dL) were added to the remaining three samples, which were recorded as the hemolysis group, icterus group and lipemia group, respectively. The information of each sample is shown in Table 6.

[0214] Table 6 NT-proBNP test sample information

[0215]

[0216] * Antigen concentration in serum samples was determined by kit (Elecsyspro BNP II STAT, Roche Diagnostics GmbH)

[0217] (3) Construction of solid phase method for sample determination

[0218] The method comprises the following steps: taking 20 μl of a sample, adding 60 μl of each of the reagent A and the reagent B prepared in Example 5 and 30 μl of the reagent D to the sample, mixing well and reacting at 37° C. for 10 minutes, performing 3 steps of magnetic separation and washing, and then adding 85 μl of the reagent C and an appropriate amount of alkaline solution. The generated light signal is captured by a photomultiplier tube, and the light value signal is converted into a concentration value through a calibration curve.

[0219] (4) Construction of homogeneous method for sample determination

[0220] The method comprises the following steps: taking 20 μl of a sample, adding 60 μl of reagent A and reagent B prepared in Example 5 to the sample, mixing well, reacting at 37° C. for 10 minutes, and then adding 85 μl of reagent C and 5 μl of 0.05 mM vitamin C. The generated light signal is captured by a photomultiplier tube, and the light value signal is converted into a concentration value through a calibration curve.

[0221] (5) Construction of the technical detection method described in the present invention

[0222] The following steps are involved:

[0223] A. Set the preset item to "NT-proBNP". After the comparison module determines that the item to be tested "NT-proBNP" meets the preset item;

[0224] B. All samples were measured using the “solid phase method”.

[0225] (6) Effect

[0226] Table 7 NT-proBNP test results of different samples

[0227]

[0228] It can be seen from the test results in Table 7 that for ultra-low concentration test items, a more accurate detection method is used after comparing and judging the preset items with the items to be tested, thereby avoiding the problem of inaccurate test results caused by directly using the homogeneous detection method, and also avoiding the influence of interfering samples on the test results. Therefore, the present invention has higher accuracy than homogeneous detection and is not affected by interference.

[0229] It should also be noted that the exemplary embodiments mentioned in the present invention describe some methods or systems based on a series of steps or devices. However, the present invention is not limited to the order of the above steps, that is, the steps can be performed in the order mentioned in the embodiments, or in a different order from the embodiments, or several steps can be performed simultaneously.

[0230] In the present invention, features described and / or illustrated for one embodiment may be used in the same or similar manner in one or more other embodiments, and / or combined with features of other embodiments or replace features of other embodiments.

[0231] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the embodiments of the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A target detection kit, characterized in that: The kit comprises reagent A and reagent B; the reagent A comprises a first binding molecule, and the first binding molecule is coupled to compound 1; the reagent B comprises a second binding molecule, and the second binding molecule is coupled to compound 2; the first binding molecule or the second binding molecule further comprises at least one connection structure I; Wherein, the compound 1 has the function of catalyzing compound 2 to generate a signal, the first binding molecule and the second binding molecule can specifically bind to the target in the sample to form a specific binding complex, and the first binding molecule and the second binding molecule are not coupled to a solid phase carrier.

2. The kit according to claim 1, characterized in that The kit further comprises a reagent C, wherein the reagent C contains compound 3; Wherein, the compound 2 and the compound 3 react to generate a detectable signal; Preferably, the compound 3 is selected from peroxides.

3. The kit according to any one of claims 1 or 2, characterized in that The compound 1 is a substance that can catalyze a substrate to produce hydroxyl radicals, including at least one of a transition metal salt and / or a complex and a peroxidase; preferably, the compound is a peroxidase.

4. The kit according to any one of claims 1 to 3, characterized in that The compound 2 is at least one of the compounds that generate photons under the action of hydroxyl radicals; preferably includes at least one of luminol, isoluminol, rofenine, acridinium ester, lucigenin, 9,10-dihydroacridine and phthaloyl hydrazide.

5. The kit according to any one of claims 1 to 4, characterized in that Compound 1 and compound 2 are coupled to the first binding molecule and the second binding molecule respectively through a flexible connection unit; preferably, the flexible connection unit is selected from polyoxyethylene ether substances, polyoxypropylene ether substances, alkyl, polyethyleneimine substances, polypeptides or blocks of the above substance constituent units.

6. The kit according to any one of claims 1 to 5, characterized in that The kit also includes an alkaline solution, and the pH value of the alkaline solution is greater than or equal to 8.

7. The kit according to any one of claims 1 to 6, characterized in that The kit also includes reagent D, which contains a solid phase carrier coupled to a connecting structure II, and the connecting structure I and the connecting structure II specifically bind to each other to form a specific binding system; preferably, the specific binding system comprises an antigen-antibody specific affinity system, an avidin-biotin specific binding system, a streptavidin-biotin specific binding system and a Tag-Catcher specific binding system.

8. The kit according to any one of claims 1 to 7, characterized in that The kit also includes a signal inhibitor, which includes ascorbic acid or its salt, phenoxazine, 2-aminophenol, 2-amino-p-chlorophenol, 2-amino-o-chlorophenol, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid TROLOXTM, 3-aminotyrosine or a salt thereof, 4-Hydroxy-2-chlorophenol, 4-Hydroxy-2-methoxyphenol, o-Hydroxy-m-chlorophenol, and at least one of the compounds of the structure shown in Formula 1, Among them, any two or three substituents among the substituted R1-R6 are -OH and / or -NH2, and the remaining substituents are -H, -F, -Cl and / or -Br, and two or three substituents are -F, -Cl and / or -Br.

9. The kit according to any one of claims 1 to 8, characterized in that The kit also includes a cleaning solution.

10. A composition for detection, characterized in that The composition contains a binding molecule, wherein the binding molecule is coupled to a substance that can catalyze a substrate to generate hydroxyl radicals or a substance that generates photons under the action of hydroxyl radicals through a flexible connection unit; Wherein, the binding molecule can specifically bind to the target to be detected; The binding molecule further contains at least one connection structure, and the binding molecule is not coupled to a solid phase carrier, and the connection structure is selected from a specific binding substance.

11. The composition according to claim 10, characterized in that The binding molecules are antibodies, antigens and / or antigen binding fragments.

12. The composition according to claim 10 or 11, characterized in that The specific binding substance is selected from any one of the two parts of the following specific binding systems, including: antibody and antigen specific binding system, avidin and biotin specific binding system, streptavidin and biotin specific binding system and Tag and Catcher specific binding system.

13. The composition according to any one of claims 9 to 12, characterized in that The compound that generates photons under the action of hydroxyl free radicals includes at least one of luminol, isoluminol, rofenine, acridinium ester, lucigenin, 9,10-dihydroacridine, phthaloyl hydrazide and derivatives of the above substances.

14. Use of the composition according to any one of claims 9 to 13 in preparing a detection product.

15. The use according to claim 14, characterized in that The product is used for the detection of blood, urine, bone marrow, cerebrospinal fluid, pleural effusion, ascites, pericardial fluid, joint fluid, hydrocele, bile and / or tissue samples; preferably blood, plasma, serum and urine samples.

16. The use according to claim 14 or 15, characterized in that The product is a test kit.

17. A judgment detection method, characterized in that: The detection method comprises the following steps: S1: Perform interference identification on the sample to be tested and obtain the interference value; S2: Compare the interference value with a preset threshold value, and select to execute steps S3A-S4A or S3B-S4B according to the comparison result; in, Step S3A includes: selecting a reagent and reacting the sample to be tested with the reagent without a solid phase carrier; Step S3B includes: selecting reagents and reacting the sample to be tested with the reagent containing the solid phase carrier, and separating impurities in the detection system; Steps S4A and S4B include: measuring the reaction system and reporting the test results.

18. A judgment detection method, characterized in that: The detection method comprises: S0: Compare and judge the test items of the sample to be tested with the preset items; and select to execute (i) or (ii) test process according to the comparison and judgment results; The (i) detection process comprises: S1: Perform interference identification on the sample to be tested and obtain the interference value; S2: Compare the interference value with the preset threshold, and select to execute S3A-S4A steps or S3B-S4B steps according to the comparison result; wherein, Step S3A includes: selecting a reagent and reacting the sample to be tested with the reagent without a solid phase carrier; Step S3B includes: selecting reagents and reacting the sample to be tested with the reagent containing the solid phase carrier, and separating impurities in the detection system; Steps S4A and S4B include: measuring the reaction system and reporting the test results; The (ii) detection process comprises: Step S3B includes: selecting reagents and reacting the sample to be tested with the reagent containing the solid phase carrier, and separating impurities in the detection system; The S4B step includes: measuring the reaction system and reporting the test results.

19. The method according to claim 17 or 18, characterized in that The interference value is compared with the preset threshold value by one or more of the following methods: 1) Using a light source to illuminate the sample to be tested or a mixed solution of the sample to be tested and a reagent, detecting the transmitted light and / or scattered light signal, and making a judgment by comparing the transmitted light and / or scattered light signal with a preset threshold; 2) By calculating the difference in absorbance of the diluted sample under dual wavelengths, the value of the serum / plasma sample is given semi-quantitatively, and compared with the preset threshold value for determination; 3) Compare the color features of the sample image with the preset threshold.

20. The detection method according to any one of claims 17 to 19, characterized in that: According to the comparison result with the preset threshold value, after the step of reacting the sample to be tested with the reagent containing the solid phase carrier, the impurity removal step is performed.

21. The detection method according to any one of claims 17 to 20, characterized in that: The reagents used in step S3A include reagent A, reagent B and reagent C; the reagents used in step S3B include reagent A, reagent B, reagent C, reagent D and cleaning solution; The reagent A contains a first binding molecule, which is coupled to compound 1; the reagent B contains a second binding molecule, which is coupled to compound 2; the first binding molecule or the second binding molecule further includes at least one connection structure I; Among them, the compound 1 has the function of catalyzing compound 2 to produce a signal, the first binding molecule and the second binding molecule can specifically bind to the target in the sample to form a specific binding complex, and the first binding molecule and the second binding molecule are not coupled to a solid phase carrier; the reagent C contains compound 3, wherein the compound 2 and compound 3 produce a detectable signal after reaction; the reagent D contains a solid phase carrier coupled to a connecting structure II, and the connecting structure I and the connecting structure II specifically bind to each other to form a specific binding system.

22. The detection method according to claim 21, characterized in that The reagents in step S3A and / or step S3B also include signal inhibitors, which include ascorbic acid or its salts, phenoxazine, 2-aminophenol, 2-amino-p-chlorophenol, 2-amino-o-chlorophenol, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid TROLOXTM, 3-aminotyrosine or a salt thereof, 4-Hydroxy-2-chlorophenol, 4-Hydroxy-2-methoxyphenol, o-Hydroxy-m-chlorophenol, and at least one of the compounds of the structure shown in Formula 1, Formula 1; Among them, any two or three substituents among the substituted R1-R6 are -OH and / or -NH2, and the remaining substituents are -H, -F, -Cl and / or -Br, and two or three substituents are -F, -Cl and / or -Br.

23. A multi-level judgment detection system, characterized in that: The detection system includes: a comparison module, an interference identification and analysis module, an impurity separation module, a reagent absorption module, an optical detection module and a signal processing module, wherein: The comparison module is used to compare the item to be tested with the preset item information; The interference identification and analysis module is used to analyze sample interference information; The impurity separation module is used to separate impurities and reduce substances that affect the test results in the detection system; The optical testing module is used to detect the signal generated by the reaction system; The signal processing module is used to process signals and convert them into visual information.

24. The detection system according to claim 23, characterized in that The impurity separation module includes a cleaning submodule, and the cleaning submodule separates impurity substances by utilizing the difference between the reagent bound to the solid phase carrier and the reagent not bound to the solid phase carrier.

25. The detection system according to claim 23 or 24, characterized in that: The detection system has at least two different detection channels for detecting high-interference samples and low-interference samples respectively.

26. The detection system according to claim 25, characterized in that The detection system further includes a sample transfer module, and the function of the sample transfer module includes: transferring the sample to different detection channels based on the interference identification result.

Citation Information

Patent Citations

  • Chemiluminescent method and compositions

    CN1067257A

  • Prescription of supersensitive enzyme accelerator for chemical luminescence for liquid

    CN1072264A

  • Magnetic microparticle-based chemiluminescent immunoassay CST1 detection kit and detection method

    CN108845141A

  • No-microspheres homogeneous luminescent system of biotin-avidin or streptavidin

    CN110779912A

  • Application of kit for detecting serum amyloid protein A by spatial proximity chemiluminescence method and detection method

    CN113514449A

Cited By

  • Multi-stage determination type high-precision detection method and system, and kit

    WO2026046220A1